Maze Therapeutics Inc. Common Stock (MAZE)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Maze as I would any early-stage biotech: not as a predictable compounder, but as a speculative claim on future medicine. The company is clinical stage, with MZE829 in phase II for APOL1 kidney disease and MZE782 phase II ready for phenylketonuria. There is no approved product, so there is no durable moat yet. The reported numbers are erratic. In FY2024, revenue was $167.5 million and net income was $52.2 million. In FY2025, revenue was not reported in the filed figures and net loss was $131.1 million. In fiscal Q1 2026, revenue was $20.0 million and net loss was $24.2 million; in fiscal Q2 2026, revenue was not reported in the filed figures and net loss widened to $44.7 million. Trailing free cash flow is negative $106.8 million, a negative 7.2% FCF yield on the $1.5 billion market cap. FairStock ratios at the 2026-10-13 close show a negative P/E of -10.93, P/B of 3.27, ROE of -37.35%, ROCE of -21.79%, and a Piotroski F-score of 3/9. Debt is modest at D/E 0.13, and the FairStock Altman Z-score of 10.62 suggests low balance-sheet risk, but that must be weighed against cash burn. The stock price is $26.66, within a $21.95-$53.65 52-week range. A FairStock score of 26/100 and no Lynch category, because only two years of filed results exist, reinforce that this is not a Graham-style bargain. It is a pipeline option: the upside depends on trial data and funding, not on present earnings.

In plain English: Maze Therapeutics is a healthcare company still testing experimental medicines for kidney and metabolic diseases; it does not yet sell an approved product. The business looks weak today because it has been losing money, its revenue is uneven, and it is spending cash. At $26.66 a share, with a $1.5 billion market value, the price does not look clearly cheap based on current numbers—the value depends mostly on whether its drug trials succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer